Eyenovia resumed patient enrollment for its phase 3 study of a progressive myopia treatment following a pause due to the COVID-19 pandemic, according to a press release.
The U.S.-based, multicenter, randomized, double-masked CHAPERONE study is aiming to enroll more than 400 children between the ages of 3 and 12 years. Subjects will receive either one of two concentrations of MicroPine or placebo.
The study is evaluating the safety and efficacy of MicroPine in the reduction of progressive myopia using the company’s proprietary atropine topical micro-formulation, delivered by the Optejet
Uncategorized